公开(公告)号：US20240060135A1

公开(公告)日：2024-02-22

申请号：US17937102

申请日：2022-09-30

Applicant: Genentech, Inc.

Inventor： Li-Fen LIU ,  Sanjeev MARIATHASAN ,  Chi Yung YUEN ,  Mahrukh HUSENI

IPC: C12Q1/6886 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/57484 ,  C07K2317/24 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/5421

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer (e.g., bladder cancer (e.g., UC) or kidney cancer (e.g., RCC)). The invention provides methods of identifying an individual having a cancer who is likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, methods for selecting a therapy for an individual having a cancer, methods of identifying an individual having a cancer who is less likely to respond to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist monotherapy, methods of monitoring the response of an individual having a cancer to treatment with an anti-cancer therapy comprising a PD-L1 axis binding antagonist, and methods of treating an individual having cancer, based on expression levels of a biomarker of the invention (e.g., one or more genes set forth in any one of Tables 1-7, e.g., IL8).

公开(公告)号：US20240141437A1

公开(公告)日：2024-05-02

申请号：US18327305

申请日：2023-06-01

Applicant: Genentech, Inc.

Inventor： Sanjeev MARIATHASAN ,  Chi Yung YUEN ,  Zoe June Fergusson ASSAF ,  Carlos Ernesto BAIS ,  Romain Francois BANCHEREAU

IPC: C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12Q1/686 ,  C12Q1/6869 ,  A61K39/00

CPC classification number: C12Q1/6886 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/686 ,  C12Q1/6869 ,  A61K2039/505 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

Abstract: The invention provides methods and compositions for treating urothelial carcinoma in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient as a neoadjuvant or an adjuvant therapy based on the presence or level of ctDNA in a biological sample obtained from the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating urothelial carcinoma in a patient.